The emerging role of botulinum toxin in the treatment of temporomandibular disorders

Oral Diseases

Volumn 13, Issue 3, 2007, Pages 253-260

  Song, P C ^a   Schwartz, J ^b   Blitzer, A ^c,d  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NONE   (United States)

Author keywords

Botulinum toxin; Headache; Temporomandibular disorders

Indexed keywords

ANTIINFLAMMATORY AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; MUSCLE RELAXANT AGENT; NARCOTIC AGENT; STEROID;

ACUPUNCTURE; ARTHROCENTESIS; ARTHROSCOPY; ARTHROTOMY; BROW PTOSIS; DIET; DIPLOPIA; EXERCISE; HEADACHE AND FACIAL PAIN; HUMAN; JAW DISEASE; MASSAGE; MUSCLE WEAKNESS; ORTHOTICS; PARALYSIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PTOSIS; REVIEW; SYMPTOMATOLOGY;

BOTULINUM TOXIN TYPE A; FACIAL PAIN; HEADACHE; HUMANS; INJECTIONS, INTRAMUSCULAR; MASTICATORY MUSCLES; NEUROMUSCULAR AGENTS; TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME;

EID: 34247379132     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2007.01352.x     Document Type: Review

References (49)

1. Ambalavanar R, Moritani M, Moutanni A, Gangula P, Yallampali C, Dessem D (2006). Deep tissue inflammation upregulates neuropeptides and evokes nociceptive behaviors which are modulated by a neuropeptide antagonist. Pain 129 : 53 68.
2. Andrew D, Greenspan JD (1999). Mechanical and heat sensitization of cutaneous nociceptors after peripheral inflammation in the rat. J Neurophysiol 82 : 2649 2656.
3. Aoki KR (2005). Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26 : 785 793.
4. Beyak MJ, Ramji N, Krol KM, Kawaja MD, Vanner SJ (2004). Two TTX-resistant Na+ currents in mouse colonic dorsal root ganglia neurons and their role in colitis-induced hyperexcitability. Am J Physiol Gastrointest Liver Physiol 287 : G845 G855.
5. Binder W, Brin MF, Bliter A, Schenrock L, Diamond B (1998). Botulinum toxin type A (BoNT-!) for migraine: an open label assessment. Mov Disord 13 : 241.
6. Binder WJ, Brin MF, Blitzer A et al (2001). Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open label study. Otolaryngol Head Neck Surg 123 : 669 676.
7. Black JD, Dolly JO (1986). Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 103 : 521 534.
8. Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K (2002). Botulinum toxin A and the cutaneous nociception in humans: a prespective, double-blind, placebo-controlled randomized study. J Neurol Sci 205 : 59 63.
9. Blitzer A, Sulica L (2001). Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 111 : 218 226.
10. Blumenfeld A, Binder WJ, Blitzer A et al (2004). The emerging role of botulinum toxin type A in headache prevention. Op Tech Otolaryngol Head Neck Surg 15 : 90 96.
11. Brin MF, Fahn S, Moskowitz C et al (1987). Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2 : 237 254.
12. Brister H, Turner JA, Aaron LA, Mancl L (2006). Self efficacy is associated with pain, functioning and coping in patients with chronic temporomandibular disorder pain. J Orofac Pain 20 : 115 124.
13. Carruthers A (1999). Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache 39 : 662 5.
14. Cheshire WP, Abashain SW, Mann JD (1994). Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59 : 65 69.
15. Cui M, Khanijou S, Rubino J, Aoki KR (2004). Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 : 125 33.
16. De Kanter RJ, Truin GJ, Burgersdijk RC et al (1993). Prevalence in the Dutch adult population and a meta-analysis of signs and symptoms of temporomandibular disorder. J Dent Res 72 : 1509 18.
17. De Wijer A, De Leeuw JR, Steenks MH, Bosnian F (1996). Temporomandibular and cervical spine disorders: self-reported signs and symptoms. Spine 21 : 1638 1646.
18. Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W (2006). Idiopathic pain disorders - pathways of vulnerability. Pain 123 : 226 230.
19. Durham PL, Cady R, Cady R (2004). Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 : 35 42.
20. Dworkin SF, Huggins KH, LeResche L et al (1990). Epidemiology of the signs and symptoms in temporomandibular disorders: clinical signs in cases and controls. J Am Dent Assoc 120 : 273 281.
21. Dworkin SF, Huggins K, Wilson LE et al (2002a). A randomized clinical trial using research diagnostic criteria for temporomandibular disorders: axis I to target clinic cases for a tailored self care TMD program. J Orofac Pain 6 : 48 63.
22. Dworkin SF, Turner JA, Mancl L et al (2002b). A randomized clinical trial of a tailored comprehensive care treatment program for temporomandibular disorders. J Orofac Pain 16 : 259 276.
23. Flake NM, Gold MS (2005). Inflammation alters sodium currents and excitability of temporomandibular joint afferents. Neurosci Lett 384 : 294 299.
24. Freund BJ, Schwartz M (2002). Relief of tension type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache 42 : 1033 1037.
25. Freund B, Schwartz M, Symington JM (2000). Botulinum toxin: a new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 38 : 466 471.
26. Gold MS, Traub RJ (2004). Cutaneous and colonic rat DRG neurons differ with respect to both baseline and PGE2-induced changes in passive and active electrophysiological properties. J Neurophysiol 91 : 2524 2531.
27. Gremillion HA (2000). The prevalence and etiology of temporomandibular disorders and orofacial pain. Tex Dent J 117 : 30 39.
28. Harriott AM, Dessem D, Gold MS (2006). Inflammation increases the excitability of master muscle afferents. Neuroscience 141 : 433 442.
29. Jankovic J, Brin MF (1997). Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 6 (Suppl. S129 S145.
30. Lipton JA, Ship JA, Larasch-Robinston D (1993). Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc 124 : 115 121.
31. Maixner W, Fillingim R, Sigurdsson A, Kincaid S, Silva S (1998). Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain: evidence for altered temporol summation of pain. Pain 76 : 71 81.
32. Mathew NT, Kaup AO (2002). The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol 4 : 365 373.
33. McFarlane TV, Blinkhorn AS, Davies RM, Kincy J, Worthington HV (2002). Orofacial pain in the community: prevalence and associated impact. Community Dent Oral Epidemiol 30 : 52 60.
34. McMillan AS, Wong MCM, Zheng J, Lam CLK (2006). Prevalence of orofacial pain and treatment seeking in Hong Kong Chinese. J Orofac Pain 20 : 218 225.
35. McNeill C, ed (1993). Epidemiology. In : Temporomandibular disorders: guidelines for classification, assessment, and management, 2nd edn. Quintessence Publishing Co. : Chicago, pp. 19 22.
36. Morris S, Benjamin S, Gray R, Bennett D (1997). Physical, psychiatric and social characteristics of the temporomandibular disorder pain dysfunction syndrome: the relationship of mental disorders to presentation. Br Dent J 182 : 255 260.
37. Ohrbach R, Stohler CS (1992). Review of the literature: a current diagnostic system. J Craniomandib Disord 6 : 307 317.
38. Piovesan EJ, Teive HG, Kowacs PA, Coletta MV, Werneck LC, Silberstein SD (2005). An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 65 : 1306 1308.
39. Pow EHN, Leung KCM, McMillan AS (2001). Prevalence of symptoms associated with temporomandibular disorders in Hong Kong Chinese. J Orofac Pain 15 : 228 234.
40. Radhakrishnan R, Moore SA, Sluka KA (2003). Unilateral carageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. Pain 104 : 567 577.
41. Schwartz M, Freund B (2002). Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain 18 : S198 S203.
42. Silberstein S, Mathew N, Saper J et al (2000). Botulinum toxin type A as a migraine preventative treatment. For the BOTOX Migraine Clinical Research Group. Headache 40 : 445 450.
43. Silbertstein SD, Gobel H, Jensen R et al (2006). Botulinum toxin type A in a prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized placebo-controlled, parallel-group study. Cephalalgia 26 : 790 800.
44. Treede RD, Meter RA, Raja SN, Campbell JN (1992). Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 38 : 397 421.
45. Volknandt W (1995). Commentary: the synaptic vesicle and its targets. Neuroscience 64 : 277 300.
46. Welch MJ, Prukiss JR, Foster KA (2000). Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 : 245 258.
47. Yoshimura N, de Groat WC (1999). Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J Neurosci 19 : 4644 4653.
48. Zenz M, Strumph M, Tryba M (1997). Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 7 : 69.
49. Zwart JA, Bovim G, Sand T, Sjaastad O (1994). Tension headache: botulinum toxin paralysis of temporal muscles. Headache 34 : 458 462.